Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience

Table 2 Platelet aggregation rate

PAR	Eptifibatide + ticagrelor (TEG)	Ticagrelor (TEG)	Eptifibatide + ticagrelor (LTA)	Ticagrelor (LTA)
Baseline	21.84 ± 10.72	21.36 ± 9.43	25.03 ± 11.96	25.50 ± 13.83
1 h	5.31 ± 2.72*^#&	25.26 ± 13.22	4.64 ± 2.69^*#&	24.55 ± 13.48
12 h	5.46 ± 2.28*^#&	24.54 ± 11.49	5.83 ± 3.21^*#&	24.75 ± 14.25
24 h	4.26 ± 2.19*^#&	24.25 ± 11.25	5.43 ± 3.12^*#&	25.76 ± 13.76
24 h after discontinuation	21.17 ± 11.21	22.55 ± 11.70	25.65 ± 12.91	26.10 ± 13.57

*P < 0.001 vs. baseline, ^#P < 0.001 vs. ticagrelor group, ^&P < 0.001 vs. 24 h after discontinuation
LTA: light transmission aggregometry; PAR: platelet aggregation rate; TEG: thromboelastography

ISSN: 1471-2261